Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Graefe's Archive for Clinical and Experimental Ophthalmology

• Publication date

  2016-01-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00417-015-3215-8PMID 26553195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetic macular morphology changes may occur in the early stage of diabetes

  2016cited by this paper
• Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy

  2015cited by this paper
• Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.

  2015cited by this paper
• Choroidal thickness measurements during central serous chorioretinopathy treatment

  2015cited by this paper
• Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT

  2015cited by this paper
• Temperament Profile in Patients with Central Serous Chorioretinopathy: A Case-Control Study

  2014cited by this paper
• Central Serous Chorioretinopathy

  2014cited by this paper
• Oral eplerenone for the management of chronic central serous chorioretinopathy.

  2014cited by this paper
• Choroidal thickness measurements during central serous chorioretinopathy treatment

  2014cited by this paper
• Retinal thickness and volume measured with enhanced depth imaging optical coherence tomography.

  2013cited by this paper
• Choroidal vessel diameter in central serous chorioretinopathy

  2013cited by this paper
• Central serous chorioretinopathy: update on pathophysiology and treatment.

  2013cited by this paper
• MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A Pilot Study

  2013cited by this paper
• Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema

  2013cited by this paper
• Central serous chorioretinopathy: a review of epidemiology and pathophysiology

  2013cited by this paper
• Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy.

  2012cited by this paper
• TYPE-A BEHAVIOR AND CENTRAL SEROUS CHORIORETINOPATHY

  2012cited by this paper
• The Effect of Topical Pranoprofen 0.1% on the Clinical Evaluation and Conjunctival HLA-DR Expression in Dry Eyes

  2012cited by this paper
• High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study

  2012cited by this paper
• Quantitative evaluation by optical coherence tomography of prophylactic efficiency of Pranopulin on macular edema after cataract surgery.

  2012cited by this paper
• Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage

  2011influential reference
• COMPARISON OF CHOROIDAL THICKNESS AMONG PATIENTS WITH HEALTHY EYES, EARLY AGE-RELATED MACULOPATHY, NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, CENTRAL SEROUS CHORIORETINOPATHY, AND POLYPOIDAL CHOROIDAL VASCULOPATHY

  2011cited by this paper
• RETINAL MICROSTRUCTURAL ABNORMALITIES IN CENTRAL SEROUS CHORIORETINOPATHY AND POLYPOIDAL CHOROIDAL VASCULOPATHY

  2011cited by this paper
• Central serous chorioretinopathy: a pathogenetic model

  2011cited by this paper
• Nonsteroidal anti-inflammatory drugs in ophthalmology.

  2010cited by this paper
• Comparison of the Effects of Prophylactic Nonsteroidal Anti-inflammatory Drugs on Macular Edema After Cataract Surgery

  2010cited by this paper
• ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY OF THE CHOROID IN CENTRAL SEROUS CHORIORETINOPATHY

  2009cited by this paper
• Effect of pranoprofen on endoplasmic reticulum stress in the primary cultured glial cells.

  2009cited by this paper
• Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

  2008cited by this paper
• Topical Pranoprofen 0.1% Is As Effective Anti-Inflammatory and Analgesic Agent as Diclofenac Sodium 0.1% After Strabismus Surgery

  2007cited by this paper
• Long‐term macular function in eyes with central serous chorioretinopathy

  2005cited by this paper
• Risk factors for central serous chorioretinopathy: a case-control study.

  2004cited by this paper
• Serous detachment of the retina.

  2003cited by this paper
• Central serous chorioretinopathy

  2003influential reference
• Topical Nonsteroidal Anti-Inflammatory Therapy in Ophthalmology

  2003cited by this paper
• Effects of Topical Corticosteroids and Nonsteroidal Anti-Inflammatory Drugs on Prostaglandin E2-Induced Aqueous Flare Elevation in Pigmented Rabbits

  2003cited by this paper
• Retinal atrophy in idiopathic central serous chorioretinopathy.

  2002cited by this paper
• FACTORS ASSOCIATED WITH REDUCED VISUAL ACUITY DURING LONG-TERM FOLLOW-UP OF PATIENTS WITH IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY

  2002cited by this paper
• Systemic findings associated with central serous chorioretinopathy.

  1999cited by this paper
• Influence of the behaviour pattern on the nocebo response of healthy volunteers.

  1995cited by this paper
• CENTRAL SEROUS CHORIORETINOPATHY AND INDOCYANINE GREEN ANGIOGRAPHY

  1994cited by this paper
• [Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy].

  1993cited by this paper
• Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid. 5th communication: antiplatelet effect of the drug and antiinflammatory effect of its main metabolite.

  1986cited by this paper
• Long-term follow-up of central serous chorioretinopathy.

  1984cited by this paper
• Medical Hypothesis, Discovery &innovation Topical Nepafenac in Treatment of Acute Central Serous Chorioretinopathy

  year unknowncited by this paper

• Use of Pranoprofen After Strabismus Surgery in Children

  2025cites this paper
• Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis

  2023cites this paper
• Update on the Management of Central Serous Chorioretinopathy

  2023cites this paper
• Case Series Pachychoroid Spectrum Disorder Findings in Patients with Coronavirus Disease 2019

  2021cites this paper
• Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium

  2021cites this paper
• Pachychoroid Spectrum Disorder Findings in Patients with Coronavirus Disease 2019

  2021cites this paper
• Insights into mechanisms of pranoprofen-induced apoptosis and necroptosis in human corneal stromal cells.

  2019cites this paper
• A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy

  2019cites this paper
• Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serious Chorioretinopathy.

  2019cites this paper
• Pranoprofen quantification in ex vivo corneal and scleral permeation samples: Analytical validation

  2018cites this paper
• One Pranoprofen drug-based metal coordination polymer: Synthesis, structure and properties

  2017cites this paper
• Comment on: “Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy”

  2016cites this paper
• Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy: author’s response

  2016cites this paper